CapVest Partners has agreed to acquire a majority stake in STADA Arzneimittel from Bain Capital and Cinven, with the two firms set to retain minority positions in the German pharmaceutical group.

The terms of the transaction were not disclosed, and completion is expected in early 2026, subject to regulatory approvals.

Bain Capital and Cinven acquired STADA in 2017 and supported its transformation into a diversified healthcare company with a focus on consumer healthcare, generics, and specialty pharmaceuticals. Under their ownership, STADA’s revenues surpassed €4bn, net sales grew at a compound annual rate of 9%, and EBITDA more than doubled. The business now employs more than 11,600 people globally.

CapVest, a long-standing healthcare investor, said it will commit significant new capital to accelerate STADA’s growth in Germany and internationally, combining organic expansion with acquisitions and operational improvements.

Matthew Fargie of CapVest said: “Peter and the entire STADA team have a best-in-class track record of performance. STADA is a unique strategic platform through which we will leverage our significant healthcare and consumer expertise to accelerate the development of the company in Germany and internationally. We intend to deploy significant new capital towards this objective.”

STADA CEO Peter Goldschmidt added: “CapVest’s focus on working closely with management in transforming the size and scale of its portfolio companies through significant capital investment, a combination of organic and acquisition led growth, operational excellence, and long-term value creation reflects the same principles that have underpinned STADA’s success to date.”

The transaction underscores private equity’s continued interest in European healthcare platforms and highlights STADA’s position as a leading international player in consumer healthcare, generics, and specialty pharmaceuticals.

If you think we missed any important news, please do not hesitate to contact us at news@pe-insights.com.

Can`t stop reading? Read more.